November 4, 2022 Release Highlights Copied
Practice Insights is pleased to announce updates in the application to support the Merit-Based Incentive Payment System (MIPS) and the Elevated Pain Worklist.
MIPS Quality Measures Dashboard
The MIPS Quality Measures dashboard will be updated with the following:
- Technical refinements were made to MIPS #110: Influenza Immunization to include Date Received as Numerator Credit. Practices will not see any changes in the numerator.
- Removal of PIMSH #3 and PIMSH #11 from the dashboard. These measures were retired for 2022 MIPS Reporting.
Elevated Pain Worklist
Technical refinements were made to better capture non-E/M visit related pain documentation in the Elevated Pain Worklist.
Status of Dashboard Updates for 2022
CMS releases updates to the quality measure specifications annually for the MIPS program and bi-annually for the OCM program. These measure specifications have been reviewed and Practice Insights is currently working on the required technical updates to align with the revised requirements. McKesson will continue to notify practices once measures have been updated based on the current 2022 requirements. The measures listed below either have no 2022 update required or have been updated.
| Measure | Description |
|---|---|
MIPS Quality Measures Dashboard |
|
| #047 | Advance Care Plan |
| #104 | Combination Androgen Deprivation Therapy for Prostate |
| #110 | Preventive Care and Screening: Influenza Immunization |
| #128 | Body Mass Index (BMI) Screening and Follow-Up Plan |
| #130 | Current Medications Documentation |
| #134 | Depression Screening |
| #143 | Pain Intensity Quantified |
| #144 | Pain Care Plan |
| #226 | Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention |
| #236 | Controlling High Blood Pressure |
| #238 | Use of High-Risk Medications in Older Adults (Inverse Measure) |
| #374 | Closing the Referral Loop |
| #450 | HER2 Targeted Therapies for Breast Cancer |
| #451 | RAS (KRAS and NRAS) Gene Mutation Testing Performed for Patients with Metastatic Colorectal Cancer who Receive Anti-epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody Therapy |
| #453 | Proportion Receiving Chemotherapy in the Last 14 Days of Life (Inverse Measure) |
| #457 | Patients Admitted to Hospice for < 3 Days |
| PIMSH#1 | Advance Care Planning in Metastatic Cancer |
| PIMSH#2 | Utilization of GCSF in Metastatic Colon/Rectal Cancer (Inverse Measure) |
| PIMSH#4 | Patient-Reported Pain Improvement |
| PIMSH#8 | Mutation Testing for Lung Cancer |
| PIMSH#9 | Supportive Care Drug Utilization in the Last 14 Days of Life (Inverse Measure) |
| PIMSH#10 | Hepatitis B Serology Testing for Prophylactic Treatment Prior to Receiving Anti CD20 Targeting Drugs |
| PIMSH#12 | COVID-19 Vaccinations |
OCM Performance Measures Dashboard 1H 2022 |
|
| OCM 4A | Pain Intensity Quantified |
| OCM 4B | Plan of Care for Pain |
| OCM5 | Depression Screening |